This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO and
Aug. 1, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, and CombiMatrix Corporation (NASDAQ: CBMX), a molecular diagnostics laboratory performing DNA-based testing services for developmental disorders and cancer, today jointly announced that the Sequenom Center for Molecular Medicine LLC (Sequenom CMM) and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis (CMA) testing services to broaden and confirm the results of noninvasive, prenatal testing (NIPT) to physicians and their patients.
Under the agreement, the two laboratories will collaboratively use their respective marketing channels and sales forces to promote the use of NIPT and CMA and work together to provide technical training to physicians and counseling, education and support services to physicians and their patients. The two companies plan to provide, when clinically appropriate, a comprehensive test result report for ordering physicians.
Sequenom is a global leader in the NIPT market, and Sequenom CMM, its wholly owned subsidiary laboratory, developed the MaterniT21
TM PLUS laboratory-developed test (LDT), a widely-ordered, noninvasive prenatal testing service for fetal chromosomal abnormalities. CombiMatrix is one of the few independent laboratories that specialize in CMA, the primary genetic test to evaluate newborns with birth defects that is now being more widely used for prenatal testing.
"The MaterniT21 PLUS test is the premier, noninvasive prenatal test on the market today, and for an important group of patients a chromosomal microarray test can be a significant adjunct for a comprehensive prenatal analysis," said
Bill Welch, President and COO of Sequenom, Inc. "CombiMatrix specializes in CMA and their technology helps further expand our product offering in the growing prenatal genetic testing marketplace."
"The collaboration with Sequenom CMM is a significant validation of the rapidly expanding acceptance of CMA as a standard of prenatal care as well as an endorsement of the services CombiMatrix provides," noted CombiMatrix CEO
"We are focused on establishing CombiMatrix as the premier specialty laboratory for chromosomal microarray analysis for prenatal testing," McDonough said. "The fact that Sequenom CMM has joined forces with us and selected us for this collaborative testing relationship demonstrates that we have made great strides in reaching our goal."